Medical Imaging

Physicians utilize medical imaging to see inside the body to diagnose and treat patients. This includes computed tomography (CT), magnetic resonance imaging (MRI), X-ray, ultrasound, fluoroscopy, angiography,  and the nuclear imaging modalities of PET and SPECT. 

Healthcare reform launches new era for nuclear medicine

While healthcare reform has been slowly evolving as a result of many acts of Congress during the past decade, it is the Affordable Care Act of 2010 (ACA), that is driving major changes in healthcare coverage, the economics of the medical industry and quality of care. The latter is being carried by a series of reporting and incentive programs that have a direct impact on the practice of nuclear medicine and molecular imaging, according to a review published March 1 in the Journal of Nuclear Medicine Technology.

Dynamic susceptibility contrast MRI could tip off early-stage Alzheimer’s

Cerebral blood flow (CBF) is an emerging indication of Alzheimer’s pathology and dynamic susceptibility contrast (DSC) MRI may be an ideal modality to track CBF in high-risk patients with mild cognitive impairment, as well as those already diagnosed with the disease, according to a study published in the June issue of Academic Radiology.

High-res detectors improve SPECT/CT evaluation of skeletal disease

SPECT/CT using high-resolution CT detector technology has been found to increase the diagnostic capabilities of SPECT when used to detect diseased bone, including osteomyelitis and other peripheral skeletal disease, and at a lower cost than high-resolution multi-detector CT, according to a study published May 23 in the Journal of Nuclear Medicine.

PET/CT powers MPI improvements

There are several advantages to PET/CT for myocardial perfusion imaging (MPI) including upgrades in quantitative analysis and biomarker technology that could provide a more complete evaluation of cardiovascular disease, according to a review published in the Journal of Nuclear Cardiology.

FDA Approves Popular European MRI Contrast Agent Dotarem

The U.S. Food and Drug Administration (FDA) has approved Dotarem (gadoterate meglumine) as the first macrocyclic and ionic gadolinium-based contrast agent (GBCA) that can be used in the United States

Other side of the coin: CT has advantages over SPECT for detection of stable CAD

In a companion piece that counters an opinion that SPECT is the best modality for first-line detection of CAD, separate experts argued that CT finds sub-clinical atherosclerosis and important coronary anatomy, providing earlier diagnoses and the option to be more aggressive with treatment, according to a review published April 10 in the Journal of Nuclear Cardiology.

Correction: Amyvid makers call for CMS coverage of amyloid imaging

The article "Amyvid makers call for CMS coverage of amyloid imaging," has been revised.

SPECT beats CT for detection of stable CAD

Some clinicians maintain that cardiac-computed tomography angiography (CCTA) bests SPECT/CT for the detection of CAD, but two expert nuclear cardiologists suggest the opposite and presented data to demonstrate their case, in a study published April 10 in the Journal of Nuclear Cardiology.